Nateglinide: a Double Blind Add-on Study With Pioglitazone for Type 2 Diabetic Patients

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to investigate the superiority of nateglinide over placebo for inadequately controlled type 2 diabetic patients with pioglitazone treatment.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Astellas Pharma Inc
• Collaborator: Ajinomoto USA, INC.
• Treatments: Nateglinide; Pioglitazone

Criteria

Inclusion Criteria:

• Type 2 diabetes mellitus under the treatment with pioglitazone

Exclusion Criteria:

• Patients who cannot follow the diet therapy and/or exercise therapy

• Type 1 diabetes mellitus